3,769
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

ORCID Icon, ORCID Icon, , ORCID Icon &
Article: 2177096 | Received 05 Jan 2023, Accepted 31 Jan 2023, Published online: 11 May 2023